<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147247</url>
  </required_header>
  <id_info>
    <org_study_id>1424-0001</org_study_id>
    <secondary_id>2019-003490-25</secondary_id>
    <nct_id>NCT04147247</nct_id>
  </id_info>
  <brief_title>A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread</brief_title>
  <official_title>An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 905681 Administered Intravenously in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine the maximum tolerated dose (MTD)/optimal&#xD;
      biological dose (OBD) of BI 905681 given as an intravenous infusion and to determine the&#xD;
      recommended dose and dosing schedule for further trials in the development of BI 905681. The&#xD;
      MTD will be defined based on the frequency of patients experiencing dose-limiting toxicities&#xD;
      (DLTs) during the MTD/DLT evaluation period, which is defined as the first cycle of&#xD;
      treatment. Separate MTDs will be determined for Schedule A and Schedule B.&#xD;
&#xD;
      The secondary objective of the trial is to determine the pharmacokinetic (PK) profile of BI&#xD;
      905681.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing adverse events (AEs) during the entire treatment period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: maximum measured concentration of BI 905681 in serum after first infusion</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz: area under the serum concentration-time curve over the time interval from 0 to the last measured time point (tz)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 905681</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 905681</intervention_name>
    <description>Infusion</description>
    <arm_group_label>BI 905681</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of an advanced, unresectable&#xD;
             and/or metastatic non-haematologic malignancy. Patient must have measurable or&#xD;
             evaluable lesions (according to Response Evaluation Criteria in Solid Tumours (RECIST)&#xD;
             v 1.1).&#xD;
&#xD;
          -  Patient who has failed conventional treatment or for whom no therapy of proven&#xD;
             efficacy exists or who is not eligible for established treatment options.&#xD;
&#xD;
          -  Patients willing to undergo mandatory tumour biopsy at the time points specified in&#xD;
             the protocol.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1 (R01-0787).&#xD;
&#xD;
          -  Adequate organ function defined as all of the following:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 x 10^9/L; haemoglobin ≥9.0 g/dL; platelets&#xD;
                  ≥100 x 10^9/L without the use of haematopoietic growth factors within 4 weeks of&#xD;
                  start of study medication.&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x the upper limit of normal (ULN), except for patients with&#xD;
                  Gilbert's syndrome: total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN.&#xD;
&#xD;
               -  Creatinine ≤1.5 x ULN. If creatinine is &gt;1.5 x ULN, patient is eligible if&#xD;
                  concurrent creatinine clearance ≥50 ml/min (measured or calculated by the Chronic&#xD;
                  Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or Japanese version&#xD;
                  of CKD-EPI formula for Japanese patients).&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN if no&#xD;
                  demonstrable liver metastases, or otherwise ≤5 x ULN&#xD;
&#xD;
               -  Alkaline Phosphatase (ALP) &lt;5 x ULN&#xD;
&#xD;
          -  At least 18 years of age at the time of consent or over the legal age of consent in&#xD;
             countries where that is greater than 18 years.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with International Conference&#xD;
             on Harmonisation (ICH) - Good Clinical Practice (GCP) and local legislation prior to&#xD;
             admission to the trial&#xD;
&#xD;
          -  Life expectancy ≥3 months at the start of treatment in the opinion of the investigator&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Osteoporosis ≥ CTCAE Grade 2&#xD;
&#xD;
          -  Osteoporotic compression fracture within 12 months prior to informed consent which is&#xD;
             clinically significant in the opinion of the investigator.&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

